PATENT CLAIM ANALYSIS

Application Number: 15750318
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "482000"]

Abstract:
Pharmaceutical compositions for the treatment of cancer are provided. In one embodiment the composition comprises Gamitrinib and a MAPK inhibitor selected from the MAPK inhibitor is selected from RAF265, AZD6244, PLX4720, PD0325901, LGX818, MEK162, vemurafenib, trametinib and dabrafenib. Methods of treating cancer are also provided.

Claim (Index 18):
The composition according to  claim 17 , wherein each said ligand is an amplification nucleic acid primer or primer pair that amplifies and detects a nucleic acid sequence of said gene transcript or, a polynucleotide probe that hybridizes to the gene's mRNA nucleic acid sequence, or an antibody or fragment of an antibody, each ligand being specific for at least gene of Table 1.

Metadata:
- Claim Count in Document: 48.0
- Percentile: 88.0
- Lexical Diversity: 1.52778
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14770994', '14387735', '14147689', '12865620', '15002457']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.787250907591111
- 35 USC 102 Novelty (BERT): 0.5394302120146128
- Combined Prediction Score: 0.7624688380334613
- Mean Citation Score: 304.030938
- Max Citation Score: 382.53238
- Similarity Product: 256.46216571217536

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test